

**Oncology Precision Medicine Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Cancer Targeted (Bladder Cancer, Blood / Hematologic Cancer, Breast Cancer, Cervical Cancer, Gastrointestinal Cancer, Head and Neck Squamous Cell Cancer, Lung Cancer, Skin Cancer and Others), Route of Administration (Oral, Intravenous and Others), Type of Molecule (Small Molecules and Biologics), Drug Class (Kinase Inhibitors, Enzyme Inhibitors, Immune Checkpoint Inhibitors and Others), Key Geographical Regions (North America (US, Canada), Europe (France, Germany, Italy, Spain and UK), Asia (China, Japan, Korea and India), Middle East and North Africa (UAE, Israel, Qatar, Rest of Middle East and North Africa) and Latin America (Brazil, Argentina, Chile and Rest of Latin America), Leading Drug Developers and Sales Forecast**

<https://marketpublishers.com/r/O3AEB9F11D74EN.html>

Date: January 2024

Pages: 468

Price: US\$ 4,799.00 (Single User License)

ID: O3AEB9F11D74EN

## **Abstracts**

Oncology Precision Medicine Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Cancer Targeted (Bladder Cancer, Blood / Hematologic Cancer, Breast Cancer, Cervical Cancer, Gastrointestinal Cancer, Head and Neck Squamous Cell Cancer, Lung Cancer, Skin Cancer and Others), Route of Administration (Oral,

Intravenous and Others), Type of Molecule (Small Molecules and Biologics), Drug Class (Kinase Inhibitors, Enzyme Inhibitors, Immune Checkpoint Inhibitors and Others), Key Geographical Regions (North America (US, Canada), Europe (France, Germany, Italy, Spain and UK), Asia (China, Japan, Korea and India), Middle East and North Africa (UAE, Israel, Qatar, Rest of Middle East and North Africa) and Latin America (Brazil, Argentina, Chile and Rest of Latin America), Leading Drug Developers and Sales Forecast

Report Link: <https://www.rootsanalysis.com/reports/oncology-precision-medicine-market.html>

The oncology precision medicine market is expected to reach USD 130 billion by 2023 anticipated to grow at a CAGR of 8.93% during the forecast period 2023-2035.

Cancer is widely recognized as a highly lethal disease, characterized by its widespread occurrence and high mortality rates on a global scale. According to data from the World Health Organization, the year 2020 saw approximately 20 million new cases of cancer and 10 million cancer-related deaths reported. Projections indicate a staggering 60% increase in these figures by the year 2040. The increase in cancer prevalence and pathogenesis can be attributed to various factors such as alcohol consumption, obesity, viral infections, and exposure to radiation and chemicals. Traditional treatment methods for cancer, including surgery, radiation therapy, and chemotherapy, are commonly employed. Complementary or alternative therapeutic approaches such as hormone therapy, immunotherapy, and nano therapy are also utilized. However, these treatments have limitations in addressing the intrinsic genetic abnormalities underlying cancer, which may stem from specific mutations in oncogenes, tumor suppressor genes, and DNA repair genes.

To address the limitations of existing treatments, the concept of precision medicine, also known as personalized medicine, has emerged. Precision medicine utilizes genomic information to develop targeted therapies tailored to individual patients. By analyzing tumor characteristics, genetic data, patient lifestyle, and environmental factors, precision medicine offers promising potential in treating cancer by moving away from a one-size-fits-all approach. Individuals with a family history of certain cancers are at a higher risk of inheriting the condition, and precision oncology enables them to undergo genetic testing to assess their risk. Early cancer screening facilitates early detection, leading to improved treatment outcomes. Notably, several precision cancer centers in the US, such as MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Mayo Clinic Cancer Center, provide advanced technologies and treatments

tailored for patients with rare or challenging cancers. Clinical trials of oncology precision medicines have demonstrated high efficacy, leading to increased participation of volunteers and consequently expanding the patient pool in such trials. This aids researchers in making better-informed decisions regarding evaluated drugs or technologies. With ongoing research and innovation in precision medicine, there is an anticipated significant increase in the adoption of targeted drugs, thereby driving growth in the oncology precision medicine market in the foreseeable future.

## Report Coverage

The report comprehensively examines the oncology in precision market based on type of cancer targeted route of administration, type of molecule, drug class, key geographical regions.

It thoroughly analyzes market influences such as drivers, restraints, opportunities, and challenges, while evaluating competitive landscapes for top players. Forecasts are provided for segment revenues across major regions.

The report presents an overview of precision medicine, specifically in the oncology field, comparing it to traditional cancer medications. It outlines the process of developing oncology precision medicines, discussing their advantages and anticipated significance in shaping the future of personalized healthcare. Challenges associated with oncology precision medicine are also addressed.

An overview of precision medicine in oncology is provided, covering its evolution, types, and application areas. The chapter also discusses the benefits of these procedures compared to traditional beauty treatments, along with their associated side effects. Key drivers of growth, new technologies, key issues, and future prospects in this field are also covered.

A comprehensive analysis of current oncology precision medicine developers is conducted, considering parameters such as establishment year, company size, headquarters, stage of development, approval body, approval region, drug designation, type of molecule, drug class, route of administration, dosage regimen, patient population, and type of cancer targeted. Additionally, the chapter presents a detailed analysis of the current landscape of discovery and preclinical stage oncology precision medicines, based on parameters such as stage of development, type of molecule, drug class, and type of cancer targeted.

Detailed profiles of companies offering precision medicine are presented, focusing on company overviews, financial information (where available), portfolio, recent advancements, and future prospects.

An analysis of partnerships established in this sector since 2018 is conducted, covering various agreements such as clinical trial agreements, commercialization agreements, drug development agreements, drug distribution agreements, drug licensing agreements, manufacturing agreements, mergers/acquisitions, process development and manufacturing agreements, research agreements, research and development agreements, service agreements, technology utilization agreements, and others.

Detail examination of completed or ongoing clinical trials in the field of oncology precision medicine is conducted, focusing on parameters such as trial registration year, patient enrollment numbers, trial phase, status, target patient demographics, gender distribution, types of cancer targeted, sponsorship or collaboration types, study design characteristics, intervention models, and trial purposes. The analysis also identifies the most active sponsors or collaborators, comprising both industry and non-industry players based on their sponsorship of clinical trials. Additionally, emerging focus areas and geographical trends are explored within this clinical trial analysis.

A case study is presented on developers of precision oncology assay kits, offering a detailed analysis across several parameters including development stage (commercialized and under development), regulatory certification and compliance, regional availability, test type, sample type, biomarker detection principle, turnaround time, cancer type targeted, and end-user demographics. Furthermore, the chapter includes insights on various assay kit developers, along with an analysis based on parameters such as establishment year, company size, and headquarters location.

## Key Market Companies

AbbVie

Anticancer Bioscience

Astellas Pharma

Astrazeneca

Bayer

Blueprint Medicines

Bristol Myers Squibb

Eli Lilly

Erasca

Genentech

GlaxoSmithKline

Hutchmed

IDEAYA Biosciences

Jiangsu Hengrui Pharmaceuticals

Johnson & Johnson Innovative Medicine

Merck

Novartis

Pfizer

Repare Therapeutics

Roche

Seagen

SpringWorks Therapeutics

Takeda Pharmaceutical

VERAXA Biotech GmbH

VRise Therapeutics

## Contents

### 1. PREFACE

- 1.1. Introduction
- 1.2. Market Share Insights
- 1.3. Key Market Insights
- 1.4. Report Coverage
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines

### 2. RESEARCH METHODOLOGY

- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Market Segmentations
- 2.7. Key Considerations
  - 2.7.1. Demographics
  - 2.7.2. Economic Factors
  - 2.7.3. Government Regulations
  - 2.7.4. Supply Chain
  - 2.7.5. COVID Impact / Related Factors
  - 2.7.6. Market Access
  - 2.7.7. Healthcare Policies
  - 2.7.8. Industry Consolidation

### 3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

- 3.1. Chapter Overview
- 3.2. Market Dynamics
  - 3.2.1. Time Period
    - 3.2.1.1. Historical Trends
    - 3.2.1.2. Current and Forecasted Estimates
  - 3.2.2. Currency Coverage
    - 3.2.2.1. Overview of Major Currencies Affecting the Market
    - 3.2.2.2. Impact of Currency Fluctuations on the Industry

### 3.2.3. Foreign Exchange Impact

#### 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market

#### 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

### 3.2.4. Recession

#### 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt

#### 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

### 3.2.5. Inflation

#### 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

#### 3.2.5.2. Potential Impact of Inflation on the Market Evolution

## 4. EXECUTIVE SUMMARY

## 5. INTRODUCTION

### 5.1. Chapter Overview

### 5.2. Precision Medicine

#### 5.2.1. Evolution of Precision Medicine

### 5.3. Oncology Precision Medicine

#### 5.3.1. Oncology Precision Medicine over Traditional Cancer Medicine

#### 5.3.2. Steps Involved in Developing Oncology Precision Medicine

#### 5.3.3. Advantages Associated with Oncology Precision Medicine

##### 5.3.3.1. Benefits to the Patients

##### 5.3.3.2. Benefits to the Healthcare Providers

##### 5.3.3.3. Benefits to the Cancer Researchers

#### 5.3.4. Challenges Associated with Oncology Precision Medicines

#### 5.3.5. Future Perspectives

## 6. ONCOLOGY PRECISION MEDICINE: MARKET LANDSCAPE

### 6.1. Chapter Overview

### 6.2. Oncology Precision Medicine: Commercialized and Clinical Stage Drugs Market Landscape

#### 6.2.1. Analysis by Stage of Development

#### 6.2.2. Analysis by Approval Body

#### 6.2.3. Analysis by Approval Region

#### 6.2.4. Analysis by Drug Designation

#### 6.2.5. Analysis by Type of Molecule



- 6.2.6. Analysis by Drug Class
- 6.2.7. Analysis by Route of Administration
- 6.2.8. Analysis by Dosage Regimen
- 6.2.9. Analysis by Patient Population
- 6.2.10. Analysis by Type of Cancer Targeted
- 6.2.11. Analysis by Stage of Development and Type of Cancer Targeted
- 6.3. Oncology Precision Medicine: Preclinical and Discovery Stage Drugs Market Landscape
  - 6.3.1. Analysis by Stage of Development
  - 6.3.2. Analysis by Type of Molecule
  - 6.3.3. Analysis by Drug Class
  - 6.3.4. Analysis by Type of Cancer Targeted
- 6.4. Oncology Precision Medicine: Developer Landscape
  - 6.4.1. Analysis by Year of Establishment
  - 6.4.2. Analysis by Company Size
  - 6.4.3. Analysis by Location of Headquarters (Region)
  - 6.4.4. Analysis by Location of Headquarters (Country)
  - 6.4.5. Analysis by Company Size and Location of Headquarters (Region)
  - 6.4.6. Most Active Players: Analysis by Number of Oncology Precision Medicines

## **7. DETAILED COMPANY PROFILES**

- 7.1. Chapter Overview
- 7.2. AstraZeneca
  - 7.2.1. Company Overview
  - 7.2.2. Financial Information
  - 7.2.3. Oncology Precision Medicine Portfolio
  - 7.2.4. Recent Developments and Future Outlook
- 7.3. Genentech
  - 7.3.1. Company Overview
  - 7.3.2. Financial Information
  - 7.3.3. Oncology Precision Medicine Portfolio
  - 7.3.4. Recent Developments and Future Outlook
- 7.4. Jiangsu Hengrui Pharmaceuticals
  - 7.4.1. Company Overview
  - 7.4.2. Oncology Precision Medicine Portfolio
  - 7.4.3. Recent Developments and Future Outlook
- 7.5. Johnson & Johnson Innovative Medicine
  - 7.5.1. Company Overview

- 7.5.2. Financial Information
- 7.5.3. Oncology Precision Medicine Portfolio
- 7.5.4. Recent Developments and Future Outlook
- 7.6. Novartis
  - 7.6.1. Company Overview
  - 7.6.2. Financial Information
  - 7.6.3. Oncology Precision Medicine Portfolio
  - 7.6.4. Recent Developments and Future Outlook
- 7.7. Pfizer
  - 7.7.1. Company Overview
  - 7.7.2. Financial Information
  - 7.7.3. Oncology Precision Medicine Portfolio
  - 7.7.4. Recent Developments and Future Outlook
- 7.8. SpringWorks Therapeutics
  - 7.8.1. Company Overview
  - 7.8.2. Oncology Precision Medicine Portfolio
  - 7.8.3. Recent Developments and Future Outlook

## **8. SHORT COMPANY PROFILES**

- 8.1. Chapter Overview
- 8.2. AbbVie
- 8.3. Anticancer Bioscience
- 8.4. Astellas Pharma
- 8.5. Bayer
- 8.6. Blueprint Medicines
- 8.7. Bristol Myers Squibb
- 8.8. Eli Lilly
- 8.9. Erasca
- 8.10. GlaxoSmithKline
- 8.11. Hutchmed
- 8.12. IDEAYA Biosciences
- 8.13. Merck
- 8.14. Repare Therapeutics
- 8.15. Roche
- 8.16. Seagen
- 8.17. Takeda Pharmaceutical
- 8.18. VERAXA Biotech
- 8.19. VRise Therapeutics

## **9. PARTNERSHIPS AND COLLABORATIONS**

- 9.1. Chapter Overview
- 9.2. Partnership Models
- 9.3. Oncology Precision Medicine: Partnerships and Collaborations
  - 9.3.1. Analysis by Year of Partnership
  - 9.3.2. Analysis by Type of Partnership
  - 9.3.3. Analysis by Year and Type of Partnership
  - 9.3.4. Analysis by Type of Partner
  - 9.3.5. Analysis by Drug Involved
  - 9.3.6. Analysis by Type of Cancer Targeted
  - 9.3.7. Most Active Players: Analysis by Number of Partnerships
  - 9.3.8. Analysis by Geography
    - 9.3.8.1. Local and International Agreements
    - 9.3.8.2. Intracontinental and Intercontinental Agreements

## **10. CLINICAL TRIAL ANALYSIS**

- 10.1. Chapter Overview
- 10.2. Scope and Methodology
- 10.3. Oncology Precision Medicine: Clinical Trial Analysis
  - 10.3.1. Analysis by Trial Registration Year
  - 10.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
  - 10.3.3. Analysis by Trial Phase
  - 10.3.4. Analysis of Number of Patients Enrolled by Trial Phase
  - 10.3.5. Analysis by Trial Registration Year and Trial Phase
  - 10.3.6. Analysis by Trial Status
  - 10.3.7. Analysis by Trial Registration Year and Trial Status
  - 10.3.8. Analysis by Target Patient Population
  - 10.3.9. Analysis by Patient Gender
  - 10.3.10. Analysis by Type of Cancer Targeted
  - 10.3.11. Analysis by Type of Sponsor / Collaborator
  - 10.3.12. Analysis by Study Design
    - 10.3.12.1. Analysis by Type of Trial Masking
    - 10.3.12.2. Analysis by Type of Intervention Model
    - 10.3.12.3. Analysis by Type of Intervention
    - 10.3.12.4. Analysis by Trial Purpose
  - 10.3.13. Most Active Sponsors / Collaborators: Analysis by Number of Clinical Trials

- 10.3.13.1. Analysis by Leading Industry Players
- 10.3.13.2. Analysis by Leading Non-Industry Players
- 10.3.14. Word Cloud Analysis: Emerging Focus Areas
- 10.3.15. Analysis by Geography
  - 10.3.15.1. Analysis of Clinical Trials by Geography
  - 10.3.15.2. Analysis of Clinical Trials by Geography and Trial Status
  - 10.3.15.3. Analysis of Patients Enrolled by Geography and Trial Status

## **11. CASE STUDY: ONCOLOGY PRECISION MEDICINE ASSAY KITS**

- 11.1. Chapter Overview
- 11.2. Oncology Precision Medicine: Assay Kits
  - 11.2.1. Analysis by Stage of Development
  - 11.2.2. Analysis by Regulatory Certification / Compliance
  - 11.2.3. Analysis by Regional Availability
  - 11.2.4. Analysis by Type of Test
  - 11.2.5. Analysis by Type of Sample Used
  - 11.2.6. Analysis by Principle of Biomarker Detection
  - 11.2.7. Analysis by Turnaround Time
  - 11.2.8. Analysis by Type of Cancer Targeted
  - 11.2.9. Analysis by Turnaround Time and Type of Cancer Targeted
  - 11.2.10. Analysis by End-user
  - 11.2.11. Analysis by Regional Availability and End-user
  - 11.2.12. Analysis by Type of Cancer Targeted and End-user
- 11.3. Oncology Precision Medicine Assay Kits: Developer Landscape
  - 11.3.1. Analysis by Year of Establishment
  - 11.3.2. Analysis by Company Size
  - 11.3.3. Analysis by Location of Headquarters (Region)
  - 11.3.4. Analysis by Location of Headquarters (Country)
  - 11.3.5. Analysis by Company Size and Location of Headquarters (Region)
  - 11.3.6. Analysis by Business Model
  - 11.3.7. Most Active Players: Analysis by Number of Oncology Precision Medicine Assay Kits

## **12. CASE STUDY: TECHNOLOGIES USED IN PRECISION MEDICINE**

- 12.1. Chapter Overview
- 12.2. Technologies Used in Precision Medicine
  - 12.2.1. Next Generation Sequencing in Precision Medicine

- 12.2.2. Nanotechnology in Precision Medicine
- 12.2.3. Molecular Imaging Technologies in Precision Medicine
- 12.2.4. Omics Technologies in Precision Medicine
- 12.2.5. Artificial Intelligence (AI) in Precision Medicine
- 12.3. Conclusion

## **13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES**

- 13.1. Chapter Overview
- 13.2. Market Drivers
- 13.3. Market Restraints
- 13.4. Market Opportunities
- 13.5. Market Challenges
- 13.6. Conclusion

## **14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET**

- 14.1. Chapter Overview
- 14.2. Assumptions and Methodology
- 14.3. Global Oncology Precision Medicine Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 14.4. Scenario Analysis
  - 14.4.1 Conservative Scenario
  - 14.4.2 Optimistic Scenario
- 14.5. Key Market Segmentations

## **15. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF CANCER TARGETED**

- 15.1. Chapter Overview
- 15.2. Key Assumptions and Methodology
- 15.3. Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035
  - 15.3.1. Bladder Cancer: Forecasted Estimates (2023-2035)
  - 15.3.2. Blood / Hematologic Cancer: Forecasted Estimates (2023-2035)
  - 15.3.3. Breast Cancer: Forecasted Estimates (2023-2035)
  - 15.3.4. Cervical Cancer: Forecasted Estimates (2023-2035)
  - 15.3.5. Gastrointestinal Cancer: Forecasted Estimates (2023-2035)

- 15.3.6. Head and Neck Squamous Cell Cancer: Forecasted Estimates (2023-2035)
- 15.3.7. Lung Cancer: Forecasted Estimates (2023-2035)
- 15.3.8. Skin Cancer: Forecasted Estimates (2023-2035)
- 15.3.9. Other Cancers: Forecasted Estimates (2023-2035)
- 15.4. Data Triangulation and Validation

## **16. ONCOLOGY PRECISION MEDICINE MARKET, BY ROUTE OF ADMINISTRATION**

- 16.1. Chapter Overview
- 16.2. Key Assumptions and Methodology
- 16.3. Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035
  - 16.3.1. Oral: Forecasted Estimates (2023-2035)
  - 16.3.2. Intravenous: Forecasted Estimates (2023-2035)
  - 16.3.3. Others: Forecasted Estimates (2023-2035)
- 16.4. Data Triangulation and Validation

## **17. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF MOLECULE**

- 17.1. Chapter Overview
- 17.2. Key Assumptions and Methodology
- 17.3. Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035
  - 17.3.1. Small Molecules: Forecasted Estimates (2023-2035)
  - 17.3.2. Biologics: Forecasted Estimates (2023-2035)
- 17.4. Data Triangulation and Validation

## **18. ONCOLOGY PRECISION MEDICINE MARKET, BY DRUG CLASS**

- 18.1. Chapter Overview
- 18.2. Key Assumptions and Methodology
- 18.3. Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035
  - 18.3.1. Kinase Inhibitors: Forecasted Estimates (2023-2035)
  - 18.3.2. Enzyme Inhibitors: Forecasted Estimates (2023-2035)
  - 18.3.3. Immune Checkpoint Inhibitors: Forecasted Estimates (2023-2035)
  - 18.3.4. Others: Forecasted Estimates (2023-2035)
- 18.4. Data Triangulation and Validation

## **19. ONCOLOGY PRECISION MEDICINE MARKET, BY KEY GEOGRAPHICAL REGIONS**

### 19.1. Chapter Overview

### 19.2. Key Assumptions and Methodology

### 19.3. Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035

#### 19.3.1. North America: Forecasted Estimates (2023-2035)

##### 19.3.1.1. US: Forecasted Estimates (2023-2035)

##### 19.3.1.2. Canada: Forecasted Estimates (2023-2035)

#### 19.3.2. Europe: Forecasted Estimates (2023-2035)

##### 19.3.2.1. France: Forecasted Estimates (2023-2035)

##### 19.3.2.2. Germany: Forecasted Estimates (2023-2035)

##### 19.3.2.3. Italy: Forecasted Estimates (2023-2035)

##### 19.3.2.4. Spain: Forecasted Estimates (2023-2035)

##### 19.3.2.5. UK: Forecasted Estimates (2023-2035)

#### 19.3.3. Asia: Forecasted Estimates (2023-2035)

##### 19.3.3.1. China: Forecasted Estimates (2023-2035)

##### 19.3.3.2. Japan: Forecasted Estimates (2023-2035)

##### 19.3.3.3. Korea: Forecasted Estimates (2023-2035)

##### 19.3.3.4. India: Forecasted Estimates (2023-2035)

#### 19.3.4. Middle East and North Africa: Forecasted Estimates (2023-2035)

##### 19.3.4.1. UAE: Forecasted Estimates (2023-2035)

##### 19.3.4.2. Israel: Forecasted Estimates (2023-2035)

##### 19.3.4.3. Qatar: Forecasted Estimates (2023-2035)

##### 19.3.4.4. Rest of Middle east and North Africa: Forecasted Estimates (2023-2035)

#### 19.3.5. Latin America: Forecasted Estimates (2023-2035)

##### 19.3.5.1. Brazil: Forecasted Estimates (2023-2035)

##### 19.3.5.2. Argentina: Forecasted Estimates (2023-2035)

##### 19.3.5.3. Chile: Forecasted Estimates (2023-2035)

##### 19.3.5.4. Rest of Latin America: Forecasted Estimates (2023-2035)

### 19.4. Data Triangulation and Validation

## **20. ONCOLOGY PRECISION MEDICINE MARKET, SALES FORECAST OF DRUGS**

### 20.1. Chapter Overview

### 20.2. Key Assumptions and Methodology

### 20.3. Blockbuster Commercialized Oncology Precision Medicine Market: Sales Forecast



- 20.3.1. ADCETRIS® Sales Forecast
- 20.3.2. Alecensa® Sales Forecast
- 20.3.3. ALUNBRIG® Sales Forecast
- 20.3.4. Avastin® Sales Forecast
- 20.3.5. Ayvakit® Sales Forecast
- 20.3.6. Braftovi®+ Mektovi® Sales Forecast
- 20.3.7. BRUKINSA® Sales Forecast
- 20.3.8. CALQUENCE® Sales Forecast
- 20.3.9. DARZALEX® Sales Forecast
- 20.3.10. Elunate® Sales Forecast
- 20.3.11. Empliciti® Sales Forecast
- 20.3.12. Enhertu® Sales Forecast
- 20.3.13. IBRANCE® Sales Forecast
- 20.3.14. ICLUSIG® Sales Forecast
- 20.3.15. IMBRUVICA® Sales Forecast
- 20.3.16. IMFINZI® Sales Forecast
- 20.3.17. INLYTA® Sales Forecast
- 20.3.18. Keytruda® Sales Forecast
- 20.3.19. Kadcyla® Sales Forecast
- 20.3.20. LENVIMA® / KISPLYX® Sales Forecast
- 20.3.21. Lumakras® / Lumykras® Sales Forecast
- 20.3.22. Mekinist® Sales Forecast
- 20.3.23. NERLYNX® Sales Forecast
- 20.3.24. NINLARO® Sales Forecast
- 20.3.25. Opdivo® Sales Forecast
- 20.3.26. Padcev® Sales Forecast
- 20.3.27. Piqray® Sales Forecast
- 20.3.28. Sprycel® Sales Forecast
- 20.3.29. Tabrecta® Sales Forecast
- 20.3.30. Tagrisso® Sales Forecast
- 20.3.31. Tassigna® Sales Forecast
- 20.3.32. Tecentriq® Sales Forecast
- 20.3.33. VENCLEXTA® Sales Forecast
- 20.3.34. Verzenio® / Verzenios Sales Forecast
- 20.3.35. Xospata® Sales Forecast
- 20.3.36. Xtandi® Sales Forecast
- 20.3.37. ZEJULA® Sales Forecast
- 20.4. NDA-filed Oncology Precision Medicine Market: Sales Forecast
  - 20.4.1. Apatinib / Rivoceranib Sales Forecast



#### 20.4.2. Elunate® Sales Forecast

### 20.5. Phase III Oncology Precision Medicine Market: Sales Forecast

#### 20.5.1. Darovasertib / IDE196 Sales Forecast

##### 20.5.1.1. Darovasertib / IDE196 Regional Sales Forecast

#### 20.5.2. Elenestinib / BLU-263 Sales Forecast

##### 20.5.2.1. Elenestinib / BLU-263 Regional Sales Forecast

#### 20.5.3. Elunate® Sales Forecast

##### 20.5.3.1. Elunate® Sales Forecast by Type of Cancer Targeted

##### 20.5.3.2. Elunate® Regional Sales Forecast

#### 20.5.4. ORPATHYS® Sales Forecast

##### 20.5.4.1. ORPATHYS® Regional Sales Forecast

#### 20.5.5. Pyrotinib Sales Forecast

##### 20.5.5.1. Pyrotinib Sales Forecast by Type of Cancer Targeted

##### 20.5.5.2. Pyrotinib Regional Sales Forecast

#### 20.5.6. SYD985 / (Vic-) trastuzumab duocarmazine) Sales Forecast

##### 20.5.6.1. SYD985 / (Vic-) trastuzumab duocarmazine) Regional Sales Forecast

#### 20.5.7. ZOLINZA® Sales Forecast

##### 20.5.7.1. ZOLINZA® Regional Sales Forecast

## **21. ONCOLOGY PRECISION MEDICINE MARKET, BY LEADING DRUG DEVELOPERS**

### 21.1. Chapter Overview

### 21.2. Key Assumptions and Methodology

### 21.3. Oncology Precision Medicine Market: Distribution by Leading Drug Developers

### 21.4. Data Triangulation and Validation

## **22. CONCLUSION**

## **23. EXECUTIVE INSIGHTS**

### 23.1. Chapter Overview

### 23.2. Allarity Therapeutics

#### 23.2.1. Company Snapshot

#### 23.2.2. Interview Transcript

### 23.3. Elephas

#### 23.3.1. Company Snapshot

#### 23.3.2. Interview Transcript

## **24. APPENDIX 1: TABULATED DATA**

## **25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS**

Table 6.1 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Developer, Brand, Stage of Development, Approval Body and Approval Region

Table 6.2 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Drug Designation

Table 6.3 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Type of Molecule, Drug Class, Route of Administration, Dosage Regimen and Patient Population

Table 6.4 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Type of Cancer Targeted

Table 6.5 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Developer and Stage of Development

Table 6.6 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Type of Molecule and Drug Class

Table 6.7 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Type of Cancer Targeted

Table 6.8 Oncology Precision Medicine: List of Developers

Table 7.1 Oncology Precision Medicine: List of Companies Profiled

Table 7.2 AstraZeneca: Company Snapshot

Table 7.3 AstraZeneca: Oncology Precision Medicine Portfolio

Table 7.4 AstraZeneca: Recent Developments and Future Outlook

Table 7.5 Genentech: Company Snapshot

Table 7.6 Genentech: Oncology Precision Medicine Portfolio

Table 7.7 Jiangsu Hengrui Pharmaceuticals: Company Snapshot

Table 7.8 Jiangsu Hengrui Pharmaceuticals: Oncology Precision Medicine Portfolio

Table 7.9 Johnson & Johnson Innovative Medicine: Company Snapshot

Table 7.10 Johnson & Johnson Innovative Medicine: Oncology Precision Medicine Portfolio

Table 7.11 Johnson & Johnson Innovative Medicine: Recent Developments and Future Outlook

Table 7.12 Novartis: Company Snapshot

Table 7.13 Novartis: Oncology Precision Medicine Portfolio

Table 7.14 Novartis: Recent Developments and Future Outlook

Table 7.15 Pfizer: Company Snapshot

Table 7.16 Pfizer: Oncology Precision Medicine Portfolio
Table 7.17 Pfizer: Recent Developments and Future Outlook
Table 7.18 SpringWorks Therapeutics: Company Snapshot
Table 7.19 SpringWorks Therapeutics: Oncology Precision Medicine Portfolio
Table 7.20 SpringWorks Therapeutics: Recent Developments and Future Outlook
Table 8.1 Oncology Precision Medicine: List of Companies Profiled
Table 8.2 Company Profile: AbbVie
Table 8.3 Company Profile: Anticancer Biosciences
Table 8.4 Company Profile: Astellas Pharma
Table 8.5 Company Profile: Bayer
Table 8.6 Company Profile: Blueprint Medicines
Table 8.7 Company Profile: Bristol Myers Squibb
Table 8.8 Company Profile: Eli Lilly
Table 8.9 Company Profile: Erasca
Table 8.10 Company Profile: GlaxoSmithKline
Table 8.11 Company Profile: Hutchmed
Table 8.12 Company Profile: IDEAYA Biosciences
Table 8.13 Company Profile: Merck
Table 8.14 Company Profile: Repare Therapeutics
Table 8.15 Company Profile: Roche
Table 8.16 Company Profile: Seagen
Table 8.17 Company Profile: Takeda Pharmaceutical
Table 8.18 Company Profile: VERAXA Biotech GmbH
Table 8.19 Company Profile: VRise Therapeutics
Table 9.1 Oncology Precision Medicine: List of Partnerships and Collaborations, 2018-2023
Table 9.2 Partnerships and Collaborations: Information on Drug Involved and Type of Cancer Targeted
Table 9.3 Partnerships and Collaborations: Information on Location of Headquarters (Country and Region) and Type of Agreement (Country and Region)
Table 11.1 Oncology Precision Medicine Assay Kits: Information on Developer, Stage of Development, Regulatory Certification / Compliance and Regional Availability
Table 11.2 Oncology Precision Medicine Assay Kits: Information on Type of Test, Type of Sample, Principle of Biomarker Detection and Turn-around Time
Table 11.3 Oncology Precision Medicine Assay Kits: Information on Type of Cancer Targeted
Table 11.4 Oncology Precision Medicine Assay Kits: Information on End-user
Table 11.5 List of Oncology Precision Medicine Assay Kit Developers
Table 21.1 List of Leading Oncology Precision Medicine Developers

Table 23.1 Allarity Therapeutics: Company Snapshot

Table 23.2 Elephas: Company Snapshot

Table 24.1 Commercialized and Clinical Stage Oncology Precision Medicine:  
Distribution by Stage of Development

Table 24.2 Commercialized and Clinical Stage Oncology Precision Medicine:  
Distribution by Approval Body

Table 24.3 Commercialized and Clinical Stage Oncology Precision Medicine:  
Distribution by Approval Region

Table 24.4 Commercialized and Clinical Stage Oncology Precision Medicine:  
Distribution by Drug Designation

Table 24.5 Commercialized and Clinical Stage Oncology Precision Medicine:  
Distribution by Type of Molecule

Table 24.6 Commercialized and Clinical Stage Oncology Precision Medicine:  
Distribution by Drug Class

Table 24.7 Commercialized and Clinical Stage Oncology Precision Medicine:  
Distribution by Route of Administration

Table 24.8 Commercialized and Clinical Stage Oncology Precision Medicine:  
Distribution by Dosage Regimen

Table 24.9 Commercialized and Clinical Stage Oncology Precision Medicine:  
Distribution by Patient Population

Table 24.10 Commercialized and Clinical Stage Oncology Precision Medicine:  
Distribution by Type of Cancer Targeted

Table 24.11 Commercialized and Clinical Stage Oncology Precision Medicine:  
Distribution by Stage of Development and Type of Cancer Targeted

Table 24.12 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution  
by Stage of Development

Table 24.13 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution  
by Type of Molecule

Table 24.14 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution  
by Drug Class

Table 24.15 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution  
by Type of Cancer Targeted

Table 24.16 Oncology Precision Medicine: Distribution of Drug Developers by Year of  
Establishment

Table 24.17 Oncology Precision Medicine: Distribution of Drug Developers by Company  
Size

Table 24.18 Oncology Precision Medicine: Distribution of Drug Developers by Location  
of Headquarters (Region)

Table 24.19 Oncology Precision Medicine: Distribution of Drug Developers by Location

of Headquarters (Country)

Table 24.20 Oncology Precision Medicine: Distribution of Drug Developers by Company Size and Location of Headquarters (Region)

Table 24.21 Most Active Developers: Distribution by Number of Oncology Precision Medicines

Table 24.22 AstraZeneca: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Table 24.23 Roche (Parent Company of Genentech): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Table 24.24 Johnson & Johnson (Parent Company of Johnson & Johnson Innovative Medicine): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Table 24.25 Novartis: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Table 24.26 Pfizer: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Table 24.27 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2023

Table 24.28 Partnerships and Collaborations: Distribution by Type of Partnership

Table 24.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2018-2023

Table 24.30 Partnerships and Collaborations: Distribution by Type of Partner

Table 24.31 Partnerships and Collaborations: Distribution by Drug Involved

Table 24.32 Partnerships and Collaborations: Distribution by Type of Cancer Targeted

Table 24.33 Most Active Players: Distribution by Number of Partnerships

Table 24.34 Partnership and Collaborations: Local and International Agreements

Table 24.35 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements

Table 24.36 Clinical Trial Analysis: Cumulative Year-wise Trend, 2018-2023

Table 24.37 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2018-2023

Table 24.38 Clinical Trial Analysis: Distribution by Trial Phase

Table 24.39 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase

Table 24.40 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2018–2023

Table 24.41 Clinical Trial Analysis: Distribution by Trial Status

Table 24.42 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2018–2023

Table 24.43 Clinical Trial Analysis: Distribution by Target Patient Population

Table 24.44 Clinical Trial Analysis: Distribution by Patient Gender

Table 24.45 Clinical Trial Analysis: Distribution by Type of Cancer Targeted

Table 24.46 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator

Table 24.47 Clinical Trial Analysis: Distribution by Type of Trial Masking

Table 24.48 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 24.49 Clinical Trial Analysis: Distribution by Type of Intervention
Table 24.50 Clinical Trial Analysis: Distribution by Trial Purpose
Table 24.51 Leading Industry Players: Distribution by Number of Clinical Trials
Table 24.52 Leading Non-Industry Players: Distribution by Number of Clinical Trials
Table 24.53 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 24.54 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Table 24.55 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Table 24.56 Oncology Precision Medicine Assay Kits: Distribution by Stage of Development
Table 24.57 Oncology Precision Medicine Assay Kits: Distribution by Regulatory Certification / Compliance
Table 24.58 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability
Table 24.59 Oncology Precision Medicine Assay Kits: Distribution by Type of Test
Table 24.60 Oncology Precision Medicine Assay Kits: Distribution by Type of Sample Used
Table 24.61 Oncology Precision Medicine Assay Kits: Distribution by Principle of Biomarker Detection
Table 24.62 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time
Table 24.63 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted
Table 24.64 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time and Type of Cancer Targeted
Table 24.65 Oncology Precision Medicine Assay Kits: Distribution by End-user
Table 24.66 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability and End-user
Table 24.67 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted and End-user
Table 24.68 Oncology Precision Medicine Assay Kit Developers: Distribution by Year of Establishment
Table 24.69 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size
Table 24.70 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Region)
Table 24.71 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Country)



Table 24.72 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size and Location of Headquarters (Region)

Table 24.73 Oncology Precision Medicine Assay Kit Developers: Distribution by Business Model

Table 24.74 Most Active Developers: Distribution by Number of Oncology Precision Medicine Assay Kits Developed

Table 24.75 Global Oncology Precision Medicine Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)

Table 24.76 Global Oncology Precision Medicine Market, 2023-2035: Conservative Scenario (USD Billion)

Table 24.77 Global Oncology Precision Medicine Market, 2023-2035: Optimistic Scenario (USD Billion)

Table 24.78 Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035

Table 24.79 Oncology Precision Medicine Market for Bladder Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.80 Oncology Precision Medicine Market for Blood / Hematologic Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.81 Oncology Precision Medicine Market for Breast Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.82 Oncology Precision Medicine Market for Cervical Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.83 Oncology Precision Medicine Market for Gastrointestinal Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.84 Oncology Precision Medicine Market for Head and Neck Squamous Cell Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.85 Oncology Precision Medicine Market for Lung Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.86 Oncology Precision Medicine Market for Skin Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.87 Oncology Precision Medicine Market for Other Cancers, Conservative, Bas

## I would like to order

Product name: Oncology Precision Medicine Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Cancer Targeted (Bladder Cancer, Blood / Hematologic Cancer, Breast Cancer, Cervical Cancer, Gastrointestinal Cancer, Head and Neck Squamous Cell Cancer, Lung Cancer, Skin Cancer and Others), Route of Administration (Oral, Intravenous and Others), Type of Molecule (Small Molecules and Biologics), Drug Class (Kinase Inhibitors, Enzyme Inhibitors, Immune Checkpoint Inhibitors and Others), Key Geographical Regions (North America (US, Canada), Europe (France, Germany, Italy, Spain and UK), Asia (China, Japan, Korea and India), Middle East and North Africa (UAE, Israel, Qatar, Rest of Middle East and North Africa) and Latin America (Brazil, Argentina, Chile and Rest of Latin America), Leading Drug Developers and Sales Forecast

Product link: <https://marketpublishers.com/r/O3AEB9F11D74EN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O3AEB9F11D74EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**



Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970